Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02918617 · ClinicalTrials.gov registry record · Phase 2
Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 203
- Enrollment target
NCT02918617: Completed Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT02918617 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 203 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02918617, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 203 participants
- Enrollment target
Study Summary
This study will investigate the effectiveness of nanohydroxyapatite (nano-HAP)-containing toothpastes and cream to relieve dentin hypersensitivity, comparing it with those of a commercial desensitizing dentifrice containing calcium sodium phosphosilicate (Novamin® technology) and a standard fluoride dentifrice containing 1,500 ppm fluoride as sodium monofluorophosphate (MFP).
Primary Outcome
Patient's response to an air stimulus is recorded on a Visual Analog Scale of 0-100 with 0 representing no pain and 100 representing the worst possible pain.
Interventions
- DRUG Control toothpaste containing Novamin® technology
- DRUG Control toothpaste containing 1500 ppm fluoride as MFP
- DRUG Test toothpaste with nano-HAP (high concentration)
- DRUG Test toothpaste with nano-HAP (low concentration)
- DRUG Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
What the finished NCT02918617 record still lists
NCT02918617 is an interventional study that assigns participants to a tested intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% higher).
The record links to 0 conditions, and to 5 interventions - of which Control toothpaste containing Novamin® technology is the first listed.
NCT02918617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02918617 about?
NCT02918617 is a clinical study titled "Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream". This study will investigate the effectiveness of nanohydroxyapatite (nano-HAP)-containing toothpastes and cream to relieve dentin hypersensitivity, comparing it with those of a commercial desensitizing dentifrice containing calcium sodium phosphosilicate (Novamin® technology) and a standard fluoride...
What is the current status of trial NCT02918617?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 203 participants. The study started on 2015-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02918617?
The interventions under investigation include: Control toothpaste containing Novamin® technology (DRUG), Control toothpaste containing 1500 ppm fluoride as MFP (DRUG), Test toothpaste with nano-HAP (high concentration) (DRUG), Test toothpaste with nano-HAP (low concentration) (DRUG), Test toothpaste with nano-HAP and (Potassium Nitrate) KNO3 (DRUG).
Who is sponsoring clinical trial NCT02918617?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02918617's enrollment target sits among peer trials
203 301st of 2000 higher than 1,700 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia